| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4436 | Rk-9123016 | Novel potent and selective SIRT2 inhibitor, increasing the acetylation level of eukaryotic translation initiation factor 5A (eIF5A) and reducing cell viability of human breast cancer cells accompanied with a decrease in c-Myc expression |
|
| DCC4437 | Rkn5755 | Novel selective inhibitor of activated fibroblasts, inhibiting the enhanced migration of fibroblasts cocultured with cancer cells by binding to β-arrestin1 and interfering with β-arrestin1-mediated cofilin signaling pathways |
|
| DCC4438 | Rl-338 | Novel potent and highly selective GPR6 inverse agonist, inhibiting GPR6 cAMP signalling in TR-FRET assays with a EC50 = 16 nM and >100 fold selectivity against GPR3 and GPR12 |
|
| DCC4439 | Rm-131 | Novel gastrocolokinetic ghrelin agonist, approximately sixfold greater potency than natural ghrelin |
|
| DCC4440 | Rm-133 | Promising pro-apoptotic agent, showing activity on various cancer cell lines |
|
| DCC4441 | Rm1490 | Novel MOR agonist |
|
| DCC4442 | Rm-581-fluo | Novel Fluorescent ER-Tracker dye, showing potent cytotoxic activity on several types of cancer cells, being accumulated into the endoplasmic reticulum (ER) as highlighted by its colocalization |
|
| DCC4443 | Rms-07 | The first irreversible covalent MPS1 inhibitor, targeting a poorly conserved cysteine in the kinase's hinge region |
|
| DCC4444 | rn-450 | Potent, reversible, non-carbonyl inhibitor of fatty acid amide hydrolase (FAAH) |
|
| DCC4445 | Rna Ligand Tppc | Novel potent and specific RNA-binding ligand, targeting riboswitches and other RNAs at proximal subsites |
|
| DCC4446 | Ro 04-5595 Hydrochloride | Selective antagonist of NMDA receptors NR2B subunits |
|
| DCC4447 | ro 115-1240 | Selective alpha1A/1L-adrenoceptor partial agonist |
|
| DCC4448 | Ro 25-6981 Benzoate | Potent and selective antagonist of NMDA glutamate receptors containing the NR2B subunit |
|
| DCC4449 | Ro 31-8220 | Potent protein kinase C (PKC) inhibitor |
|
| DCC4450 | Ro 32-7315 | ADAM17-selective inhibitor |
|
| DCC4451 | Ro 48-8587 | Competitive AMPA receptor antagonist |
|
| DCC4452 | Ro 64-5229 | Selective, non-competitive Metabotropic_glutamate_receptor>mGlu2 antagonist |
|
| DCC4453 | Ro 8-4304 | Novel NR2B selective, non-competitive, voltage-independent antagonist |
|
| DCC4454 | Ro 8-4304 Hydrochloride | NMDA receptor antagonist , specifically suppressing the severe autoimmune phenotypes of chs3-2D (chilling sensitive 3, 2D), including the arrested growth morphology and heightened PR (Pathogenesis Related) gene expression |
|
| DCC4455 | Ro-09-4609 | Potent and selective Candida albicans N-myristoyltransferase (CaNmt) inhibitor |
|
| DCC4456 | Ro-09-4879 | Potent and selective Candida albicans N-myristoyltransferase (CaNmt) inhibitor, exhibiting antifungal activity in vivo |
|
| DCC4457 | Ro-23-7553 | Vitamin D analogue, showing significant in vitro and in vivo antitumor activity. |
|
| DCC4458 | Ro26-4550 Tfa Salt | Novel reversible inhibitor of interleukin-2 (IL-2) |
|
| DCC4459 | Ro31-4724 | Dual inhibitor of HDAC and MMP |
|
| DCC4460 | ro3206145 | Potent and selective inhibitor of the p38 MAPK catalytic domain |
|
| DCC4461 | Ro-363 | Beta(1) adrenoceptor-selective agonist |
|
| DCC4462 | Ro4432717 | Novel mGlu2/3 negative allosteric modulator (NAM) |
|
| DCC4463 | Ro4491533 | Selective negative allosteric modulator of mGlu3 |
|
| DCC4464 | Ro4583298 | Novel highly potent dual NK1/NK3 receptor antagonist |
|
| DCC4465 | Ro4597014 | Novel Glucokinase Activator for the Treatment of Type 2 Diabetes |
|
